RevOpsis and Kemwell Collaborate to Enhance Biologic Development

RevOpsis Therapeutics has forged a strategic partnership with Kemwell Biopharma, a contract development and manufacturing organization, to expedite the production of new multispecific biologics. This collaboration aims to accelerate the development of RevOpsis’ lead candidate, RO-104, a tri-specific biologic intended for the treatment of neovascular age-related macular degeneration (nAMD).

Under the terms of the agreement, Kemwell will manufacture RO-104, a biologic that targets three validated aspects of nAMD. This partnership leverages Kemwell's expertise in biologics manufacturing and RevOpsis’ innovative Rev-Mod platform to streamline the development process for multispecific biologics.

The collaboration will provide RevOpsis with an integrated biologics development solution, facilitating a swift transition from pre-clinical studies to first-in-human clinical trials. This aims to not only advance the development of RO-104 but also enhance the broader platform for multispecific biologics.

The combination of RevOpsis’ plug-and-play multispecific biologics platform with Kemwell’s extensive expertise in biologics development and manufacturing is expected to accelerate the discovery of new therapeutics. This will help advance these therapies to the investigational new drug (IND) submission stage more quickly.

The partnership is structured to connect preclinical work, process development, and clinical production in a way that minimizes the complexity and timelines usually associated with early Good Manufacturing Practices (GMP) processes. By integrating these stages, the collaboration aims to reduce the time needed to develop and produce high-quality biologics.

Ram Bhandari, co-founder and interim CEO of RevOpsis, emphasized the significance of this partnership. "Partnering with Kemwell is a pivotal step in accelerating the development of our lead candidate, RO-104, and advancing our pipeline of innovative multispecific biologics," he said. Bhandari highlighted Kemwell’s strong track record in high-quality biologics manufacturing and their efficiency in reducing development timelines. He also pointed out that the combination of Kemwell’s manufacturing expertise and RevOpsis’ proprietary Rev-Mod platform ensures the efficient delivery of transformative therapies to patients.

Bhandari noted that this collaboration aligns with RevOpsis’ mission to develop groundbreaking treatments quickly and bring them to patients around the world. The alliance is expected to significantly bolster the capabilities of both companies in bringing innovative treatments to market, thereby potentially transforming the landscape of biologics for conditions such as nAMD.

In summary, the strategic partnership between RevOpsis and Kemwell aims to speed up the development of the tri-specific biologic RO-104 and other multispecific biologics. By leveraging each company’s strengths, the collaboration seeks to reduce development times and complexities, ultimately aiming to deliver transformative therapies to patients more efficiently. This partnership epitomizes a concerted effort to bring innovative treatments to the market swiftly, aligning with RevOpsis’ overarching mission to deliver groundbreaking medical solutions globally.